TherapeuticsMD, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

TXMD$1.69-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except per share amounts)

	As of December 31,
	2025	2024
Assets:
Current assets:
Cash and cash equivalents	$7,483	$5,059
Royalty receivable, current portion	3,525	3,562
Prepaid and other current assets	3,437	3,638
Total current assets	14,445	12,259
License rights and other intangible assets, net	3,761	4,321
Right of use assets, net	5,293	6,102
Royalty receivable, long term	13,713	16,010
Other non-current assets	444	130
Total assets	$37,656	$38,822
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable	$377	$258
Accrued expenses and other current liabilities	1,741	2,127
Current liabilities of discontinued operations	2,667	2,781
Total current liabilities	4,785	5,166
Operating lease liabilities	5,122	5,542
Other non-current liabilities	873	744
Total liabilities	10,780	11,452
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, par value $0.001; 32,000 and 32,000 shares authorized, 11,574 and 11,532 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	11	11
Additional paid-in capital	979,256	979,181
Accumulated deficit	(952,391)	(951,822)
Total stockholders’ equity	26,876	27,370
Total liabilities and stockholders’ equity	$37,656	$38,822

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.